Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Post by SABBOBCATon Dec 12, 2022 3:51pm
218 Views
Post# 35166934

Daily Volume

Daily Volume

Hey Trogarzon, I am also feeling your pain, but as a rule of thumb for markets, if you make up over 30% of the daily volume, you're going to have a bad time... perhaps the same holds true for this message board? I am not wanting to insult or dismiss your frustrations, but there isn't much thast hasn't been said at this point. 

We know the odds of hearing anything before the new year are low, so as tax loss selling comes in we could grind lower. We are in a black out period so insider buying is off the table asside from next weeks option expiry. However, there is opportunity for a reversal in the new year, so this could be quite the buying opportunity for some investors. 

On the new news front, I finally heard back from Elif and was not surprised by the response. Reiterated the PR and leaned heavily on the fact that this is a pause in the study, not a halt. My gut is telling me that they have some ducks in the pond, but they need to sort out how to best line them up before going to the market. 

<< Previous
Bullboard Posts
Next >>